Immix Biopharma (IMMX) Competitors

Immix Biopharma (NASDAQ:IMMX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Is IMMX or ELYM more profitable?

Eliem Therapeutics' return on equity of -31.45% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-101.56%	-86.70%
Eliem Therapeutics	N/A	-31.45%	-30.43%

Which has higher valuation and earnings, IMMX or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$15.43M	-$0.89	-2.93
Eliem Therapeutics	N/A	N/A	-$35.12M	-$1.47	-3.16

Which has more volatility & risk, IMMX or ELYM?

Immix Biopharma has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Do analysts rate IMMX or ELYM?

Immix Biopharma presently has a consensus target price of $14.00, suggesting a potential upside of 436.40%. Given Immix Biopharma's higher probable upside, research analysts clearly believe Immix Biopharma is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do institutionals and insiders hold more shares of IMMX or ELYM?

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 55.9% of Immix Biopharma shares are held by insiders. Comparatively, 3.2% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer IMMX or ELYM?

Eliem Therapeutics received 5 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.

Company	Underperform	Outperform
Immix Biopharma	Outperform Votes 4 100.00%	Underperform Votes No Votes
Eliem Therapeutics	Outperform Votes 9 56.25%	Underperform Votes 7 43.75%

Does the media prefer IMMX or ELYM?

In the previous week, Eliem Therapeutics had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 9 mentions for Eliem Therapeutics and 3 mentions for Immix Biopharma. Eliem Therapeutics' average media sentiment score of 0.36 beat Immix Biopharma's score of -0.03 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eliem Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immix Biopharma and Eliem Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.